JP2007534737A - ７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体、ならびにその治療的に許容される塩、それらを含有する製薬調製物および活性剤を生成するプロセス - Google Patents

７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体、ならびにその治療的に許容される塩、それらを含有する製薬調製物および活性剤を生成するプロセス Download PDF

Info

Publication number
JP2007534737A
JP2007534737A JP2007510131A JP2007510131A JP2007534737A JP 2007534737 A JP2007534737 A JP 2007534737A JP 2007510131 A JP2007510131 A JP 2007510131A JP 2007510131 A JP2007510131 A JP 2007510131A JP 2007534737 A JP2007534737 A JP 2007534737A
Authority
JP
Japan
Prior art keywords
general formula
alkyl
pyrrolo
methine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007510131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007534737A5 (enExample
Inventor
ヤーノシュ ソルチャーニィ
ラズロ オルフィ
ジェルジ ケーリ
フリジェシュ ワーチェク
エリカ ピンター
ジュジャンナ ヘイエシュ
タマーシュ シュッツ
ヨージェフ ネメス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2007534737A publication Critical patent/JP2007534737A/ja
Publication of JP2007534737A5 publication Critical patent/JP2007534737A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2007510131A 2004-04-29 2005-04-25 ７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体、ならびにその治療的に許容される塩、それらを含有する製薬調製物および活性剤を生成するプロセス Withdrawn JP2007534737A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0400891A HUP0400891A2 (en) 2004-04-29 2004-04-29 7h-pyrrolo[2,3-d]pyrimidine derivatives, their pharmaceutically acceptable salts, pharmaceutical compositions containing them and process for the production of the compounds
PCT/HU2005/000040 WO2005105804A1 (en) 2004-04-29 2005-04-25 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES, AS WELL AS THEIR THERAPEUTICALLY ACCEPTABLE SALTS, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND PROCESS FOR PRODUCTION THE ACTIVE AGENT

Publications (2)

Publication Number Publication Date
JP2007534737A true JP2007534737A (ja) 2007-11-29
JP2007534737A5 JP2007534737A5 (enExample) 2008-06-19

Family

ID=89982174

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007510131A Withdrawn JP2007534737A (ja) 2004-04-29 2005-04-25 ７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体、ならびにその治療的に許容される塩、それらを含有する製薬調製物および活性剤を生成するプロセス

Country Status (13)

Country Link
US (1) US20080214583A1 (enExample)
EP (1) EP1756110B1 (enExample)
JP (1) JP2007534737A (enExample)
KR (1) KR20070047737A (enExample)
CN (1) CN1972946A (enExample)
AT (1) ATE462706T1 (enExample)
AU (1) AU2005238287A1 (enExample)
CA (1) CA2564277A1 (enExample)
DE (1) DE602005020281D1 (enExample)
HU (1) HUP0400891A2 (enExample)
IL (1) IL178906A0 (enExample)
RU (1) RU2391344C2 (enExample)
WO (1) WO2005105804A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2873971A1 (en) * 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyrimidines
WO2014145576A2 (en) * 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
EP3194399B1 (en) 2014-09-17 2019-04-10 Pécsi Tudományegyetem New agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders
RU2603770C2 (ru) * 2014-11-28 2016-11-27 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Замещенные пиразинопиримидиноны как блокаторы trpa1 каналов, фармацевтическая композиция, способы их получения и применения
CN110483526B (zh) * 2019-09-09 2021-10-01 辽宁大学 含芳基腙结构的吡唑并[1,5-a]嘧啶类衍生物及其应用
CN119613409A (zh) * 2024-12-05 2025-03-14 浙江工业大学 吡咯并[2,3-d]嘧啶衍生物及其在制备抗炎药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2818676A1 (de) * 1978-04-27 1979-11-08 Troponwerke Gmbh & Co Kg Substituierte 5,6-dimethylpyrrolo 2,3-d pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO1999059998A1 (en) * 1998-05-19 1999-11-25 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES
RU2001111033A (ru) * 1998-09-18 2003-05-20 Басф Акциенгезелльшафт (De) Пирролопиримидины в качестве ингибиторов протеинкиназ
CN1195755C (zh) * 1999-12-10 2005-04-06 辉瑞产品公司 吡咯并[2,3－d]嘧啶化合物
MX2007001399A (es) * 2004-08-02 2007-04-18 Osi Pharm Inc Compuestos que inhiben pirrolopirimidina multi-cinasa aril-amino sustituidas.

Also Published As

Publication number Publication date
RU2006141393A (ru) 2008-06-10
CN1972946A (zh) 2007-05-30
WO2005105804A1 (en) 2005-11-10
CA2564277A1 (en) 2005-11-10
EP1756110B1 (en) 2010-03-31
DE602005020281D1 (de) 2010-05-12
RU2391344C2 (ru) 2010-06-10
EP1756110A1 (en) 2007-02-28
US20080214583A1 (en) 2008-09-04
HUP0400891A2 (en) 2006-04-28
HU0400891D0 (en) 2004-07-28
IL178906A0 (en) 2007-03-08
AU2005238287A1 (en) 2005-11-10
ATE462706T1 (de) 2010-04-15
KR20070047737A (ko) 2007-05-07

Similar Documents

Publication Publication Date Title
JP2002543199A (ja) ホスホジエステラーゼＩＶを阻害する１−アミノトリアゾロ［４，３−ａ］キナゾリン−５−オン、および／または−５−チオン
JP6916562B2 (ja) 化合物、その薬学的に許容される塩、溶媒和物、立体異性体及び互変異性体、並びに薬物組成物、過剰増殖性障害治療剤、過剰増殖性障害予防剤、薬物、癌治療剤、癌予防剤、及びキナーゼシグナル伝達調節剤
CN110885332A (zh) 一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用
JP2007534737A (ja) ７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体、ならびにその治療的に許容される塩、それらを含有する製薬調製物および活性剤を生成するプロセス
WO2022005961A1 (en) Prpk inhibitors
EP3397640B1 (en) Xanthine derivative inhibitors of bet proteins
CN120302969A (zh) 可用作iap抑制剂的化合物和组合物
Abdel Rahman et al. Synthesis and anticancer activity evaluation of New 1, 2, 4-Triazolyl-quinazoline hybrid compounds and their pyrazolopyridine analogs
CN114773350A (zh) 一种伐地那非类似物及其合成方法和应用
CN102010418B (zh) 高喜树碱类化合物及其作为药物的用途
EP1248787B1 (en) NOVEL SUBTITUTED PYRAZOLO[4,3-e]DIAZEPINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, USE AS MEDICINAL PRODUCTS AND PROCESSES FOR PREPARING THEM
JPH02286684A (ja) チエノ‐トリアゾロ‐ジアゼピンのスルホニル誘導体、その製造方法及びそれを含有する医薬組成物
JP2023071839A (ja) キサンチンオキシダーゼを阻害するためのヒドラジノプリン化合物及びトリアゾロプリン化合物
AU2012322750B2 (en) 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d] pyrimidine derivatives, their manufacture and their use as antiviral active substances
JP2007534737A5 (enExample)
CN117510413B (zh) 一种dclk1激酶抑制剂及其制备方法和应用
HK1106235A (en) 7h-pyrrolo[2,3-d]pyrimidine derivatives, as well as their therapeutically acceptable salts, pharmaceutical preparations containing them and process for production the active agent
US6962912B2 (en) Substituted pyrazolo[4,3-e]diazepines, pharmaceutical compositions containing them, use as medicinal products and processes for preparing them
CA2631034A1 (en) Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents
CN120682237A (zh) 吲哚并饱和环类化合物或其衍生物及其应用
JPH01228991A (ja) 気管支拡張剤としての置換１，２，４−トリアゾロ〔１，５−ａ〕トリアジン
JP2000038389A (ja) ピラゾロピリミジン化合物及びキサンチンオキシダーゼ阻害剤
JPH07316162A (ja) 三環式化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080423

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100426